Jeffrey P. Nadler

2.5k total citations · 1 hit paper
28 papers, 1.9k citations indexed

About

Jeffrey P. Nadler is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jeffrey P. Nadler has authored 28 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 15 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Jeffrey P. Nadler's work include HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (13 papers). Jeffrey P. Nadler is often cited by papers focused on HIV Research and Treatment (15 papers), HIV/AIDS drug development and treatment (14 papers) and HIV/AIDS Research and Interventions (13 papers). Jeffrey P. Nadler collaborates with scholars based in United States, South Africa and Belgium. Jeffrey P. Nadler's co-authors include Anders Karlsson, Michael W. Dunne, Bonaventura Clotet, Andrzej Horban, John F. Sullivan, Jacob Lalezari, Edwin DeJesus, Elna van der Ryst, Michael Wohlfeiler and Nathan Clumeck and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Jeffrey P. Nadler

27 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey P. Nadler United States	14	1.1k	1.0k	632	257	240	28	1.9k
Howard Mayer United States	13	1.0k 0.9×	1.2k 1.1×	434 0.7×	162 0.6×	281 1.2×	15	1.7k
Lise Cuzin France	27	1.1k 1.0×	770 0.8×	688 1.1×	409 1.6×	200 0.8×	101	1.8k
John C. Pottage United States	24	1.0k 0.9×	607 0.6×	929 1.5×	108 0.4×	218 0.9×	54	1.8k
Renato Maserati Italy	26	979 0.9×	727 0.7×	380 0.6×	402 1.6×	162 0.7×	104	1.7k
Karin L. Klingman United States	22	1.5k 1.4×	1.2k 1.2×	478 0.8×	628 2.4×	145 0.6×	51	2.4k
Mauro Andreotti Italy	23	934 0.8×	874 0.9×	442 0.7×	242 0.9×	555 2.3×	99	1.8k
Louise Pedneault United States	17	2.2k 2.0×	1.9k 1.8×	885 1.4×	439 1.7×	258 1.1×	32	3.0k
Rodolphe Thiébaut France	20	745 0.7×	692 0.7×	519 0.8×	211 0.8×	179 0.7×	41	1.5k
Beverly E. Sha United States	29	828 0.7×	722 0.7×	1.1k 1.7×	226 0.9×	451 1.9×	84	2.4k
Leslie Jonas United States	10	1.7k 1.6×	1.7k 1.6×	486 0.8×	234 0.9×	189 0.8×	11	2.2k

Countries citing papers authored by Jeffrey P. Nadler

Since Specialization

Citations

This map shows the geographic impact of Jeffrey P. Nadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Nadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Nadler more than expected).

Fields of papers citing papers by Jeffrey P. Nadler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Nadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Nadler. The network helps show where Jeffrey P. Nadler may publish in the future.

Co-authorship network of co-authors of Jeffrey P. Nadler

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey P. Nadler. A scholar is included among the top collaborators of Jeffrey P. Nadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey P. Nadler. Jeffrey P. Nadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →

Haubrich, Richard, Philippe Chiliade, Amy E. Colson, et al.. (2007). Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 21(6). F11–F18. 96 indexed citations

Nadler, Jeffrey P. & Michael C. Phillips. (2005). New HIV drugs in development, 2005. Current Infectious Disease Reports. 7(3). 221–226. 1 indexed citations

Nadler, Jeffrey P.. (2003). New Anti-HIV Protease Inhibitors Provide More Treatment Options. AIDS Patient Care and STDs. 17(11). 551–564. 4 indexed citations

Gray, Glenda, et al.. (2003). The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 35(1). 22–32. 120 indexed citations

Nadler, Jeffrey P., Joseph Gathe, Richard B. Pollard, et al.. (2003). Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infectious Diseases. 3(1). 10–10. 11 indexed citations

Lieb, Spencer, et al.. (2002). Predicting Death From HIV/AIDS: A Case-Control Study From Florida Public HIV/AIDS Clinics. JAIDS Journal of Acquired Immune Deficiency Syndromes. 30(3). 351–358. 25 indexed citations

Katner, Harold, Dávid Paár, Jeffrey P. Nadler, et al.. (2002). Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 200-mg Regimen in HIV-Infected Adults Failing a Protease Inhibitor Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 31(5). 483–487. 8 indexed citations

Cohen, Calvin, Susan C. Hunt, Michael Sension, et al.. (2002). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16(4). 579–588. 126 indexed citations

10.

Allison, Robert D., et al.. (2002). Daily Dosing of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases. 34(5). 686–692. 33 indexed citations

11.

Lieb, Spencer, Robert G. Brooks, Richard S. Hopkins, et al.. (2002). Predicting Death From HIV/AIDS: A Case-Control Study From Florida Public HIV/AIDS Clinics. JAIDS Journal of Acquired Immune Deficiency Syndromes. 30(3). 351–358. 4 indexed citations

12.

Davey, Richard T., Robert L. Murphy, Francesco Graziano, et al.. (2000). Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy. JAMA. 284(2). 183–183. 138 indexed citations

13.

Haas, David W., James P. Lavelle, Jeffrey P. Nadler, et al.. (2000). A Randomized Trial of Interferon alpha Therapy for HIV Type 1 Infection. AIDS Research and Human Retroviruses. 16(3). 183–190. 42 indexed citations

14.

Ormerod, L. David, Peter R. Pavan, Jeffrey P. Nadler, et al.. (1998). Rapidl y Progressiv e Herpeti c Retina l Necrosis : A Blindin g Diseas e C of Advance dDS. Clinical Infectious Diseases. 26(1). 34–45. 42 indexed citations

15.

Nadler, Jeffrey P.. (1996). Early Initiation of Antiretroviral Therapy for Infection with Human Immunodeficiency Virus: Considerations in 1996. Clinical Infectious Diseases. 23(2). 227–230. 2 indexed citations

16.

Brown, Mark A. & Jeffrey P. Nadler. (1996). INFECTIONS IN HIV-INFECTED PATIENTS WITH MALIGNANCY. Infectious Disease Clinics of North America. 10(2). 401–412.

17.

Greene, John N., et al.. (1993). Case Report: Yersinia enterocolitica Necrotizing Pneumonia in an Immunocompromised Patient. The American Journal of the Medical Sciences. 305(3). 171–173. 5 indexed citations

18.

Rechtman, David J. & Jeffrey P. Nadler. (1991). Abdominal Abscess Due to Cardiobacterium hominis and Clostridium bifermentans. Clinical Infectious Diseases. 13(3). 418–419. 11 indexed citations

19.

Nadler, Jeffrey P., et al.. (1991). Amoxicillin-Clavulanic Acid for Treating Drug-Resistant Mycobacterium tuberculosis. CHEST Journal. 99(4). 1025–1026. 89 indexed citations

20.

Wittner, Murray, et al.. (1982). Trypanosoma cruzi: Colony formation and clonal growth in agar. Experimental Parasitology. 53(2). 255–261. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact